Compare MG & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MG | ESPR |
|---|---|---|
| Founded | 1978 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.4M | 898.5M |
| IPO Year | 2009 | 2013 |
| Metric | MG | ESPR |
|---|---|---|
| Price | $13.24 | $3.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 195.8K | ★ 6.5M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.33 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $715,300,000.00 | $303,802,000.00 |
| Revenue This Year | $1.46 | $25.45 |
| Revenue Next Year | $3.61 | N/A |
| P/E Ratio | $22.87 | ★ N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $7.06 | $0.69 |
| 52 Week High | $13.43 | $4.13 |
| Indicator | MG | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 67.31 | 59.26 |
| Support Level | $12.20 | $3.63 |
| Resistance Level | $13.05 | $4.13 |
| Average True Range (ATR) | 0.49 | 0.20 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 93.76 | 59.00 |
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.